Blood test to predict response in esophagus cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether a special blood test can help predict how well treatment will work for people with stage II–IVA esophageal squamous cell carcinoma. It may help doctors identify who is more likely to benefit from therapy, based on changes seen in the blood over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage II–IVA esophageal squamous cell carcinoma
- You are 18 years or older
- You can take care of yourself and are generally active (ECOG score 0–1)
- You expect to be able to live at least 6 more months
- You agree to attend study visits and complete extra blood tests and procedures
- You have no other major cancer and no other serious medical problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial uses a blood test to track genetic changes in esophageal cancer over time. It aims to see if these changes can show how well treatment is working.
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Hear when a new Squamous Cell Carcinoma of Esophagus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.